Finnish rivers transport carbon to Baltic Sea at an increasing rate

The amount of carbon transported via Finnish rivers to the Baltic Sea has risen substantially in the past few decades. This was found in a collaborative study by the University of Helsinki, Aarhus University and the Finnish Environment Institute. The researchers don’t know the exact effects yet.

The researchers investigated changes in the amount of organic carbon by exploring water-quality monitoring data for 30 rivers and a period of 25 years. The data demonstrated that Finnish rivers now transport 280,000 tonnes more carbon to the Baltic Sea each year than they did in the early 1990s.

Previous studies have shown that the riverine total organic carbon (TOC) load to the Baltic Sea is closely connected to precipitation: the load in a dry year may be less than half of that in a rainy year. Considerable year-on-year variation has hindered the observation of long-term trends, but the dataset collected in recent decades with modern measuring techniques is now sufficiently extensive for reliable assessments.

“We found that TOC concentrations have increased in almost every river since the early 1990s. When combined with discharges that have remained unchanged or increased, TOC discharge to the Baltic Sea has increased considerably: by almost 50% from 1993,” explains Eero Asmala, a postdoctoral researcher at the Faculty of Biological and Environmental Sciences, University of Helsinki.

The phenomenon can be attributed, in particular, to climate change and the associated increases in precipitation and temperature. The researchers discovered that the rise in TOC concentrations can be explained in half of the cases by changes in discharge, which has been caused, in turn, by changes in precipitation. In addition, increasing temperatures and decreasing acidity contributed to an increase in TOC concentrations observed in some areas. Land use also affected the growth of TOC concentrations.

“The larger the share of a catchment drained, the more TOC concentrations had increased. The rise in concentrations was approximately 20% in the least drained catchments, whereas it was twice as large in the most drained catchments,” notes Antti Räike, senior researcher at the Finnish Environment Institute.

The rising TOC concentrations and discharges of Finnish rivers have coincided with the decreasing TOC contents in Finnish soil. It is possible that at least some of the carbon that has disappeared from the soil has been transported by rivers to the Baltic Sea.

The increasing TOC concentration makes waters turbid and decreases water transparency. In addition, the increased organic load increases the risk of hypoxia in bottom waters.

“On balance, we still do not know much about how the carbon that ends up in the Baltic Sea affects the coastal ecosystem,” Asmala says.

However, several research projects at the University of Helsinki are currently exploring the climate effects of, in particular, carbon transported to coastal waters.

Story Source:

Materials provided by University of Helsinki. Note: Content may be edited for style and length.

Share Button

Health24.com | Winning the fight against TB

Dr Laura Trivino-Duran of Médecins sans Frontières (MSF), commonly known as Doctors Without Borders, says the mortality rate related to the injectables regimen treating TB was high and alarming. “It became so obvious that we couldn’t continue with the injectables, then the South African government decided to move ahead and get rid of the injectables fully and implement the World Health Organisation (WHO) recommendation in terms of SHORRT course regime without injectables.”

SHORRT stands for shorter highly-effective oral regimens for rifampicin-resistant tuberculosis therapy. It is now offered to all rifampicin resistant-tuberculosis (RR-TB) patients as a first option, and as of January this year, more than 95% of people living with RR-TB have been offered this regimen.

Global guidelines to treat TB 

The WHO estimates that 480 000 people developed multi-drug-resistant tuberculosis (MDR-TB) in 2015 and 190 000 people died as a result of it. “MDR-TB cannot be treated with the standard six month course of first-line medication which is effective in most TB patients. Patients with rifampicin-resistant or MDR-TB are treated with a different combination of second-line drugs, usually for 18 months or more,” the organisation says. The WHO updated its treatment guidelines for drug-resistant TB in May 2016 and included a recommendation on the use of the shorter MDR-TB regimen under specific conditions.

“South Africa is contributing, regionally and globally, to the biggest number of patients in the SHORRT regimen,” says Trivino-Duran. She says the great thing about SHORRT therapy is that “you don’t have to go to the clinic every day because you don’t need to have an injectable every day”.

Southern African countries unite  

At a recently held two-day workshop in Johannesburg hosted by South Africa’s health department and MSF, professionals from Southern Africa came together to see how they can support each other for the enrolment of the SHORRT course regimen to be successful.  

“As a region we need to have a conversation whereby we’re all asking for the same things; somehow we’re all struggling with the same problems such as funding for drugs, training, transport and many more. But funding is not the only issue, there is also other issues that are important to overcome,” says Trivino-Duran. 

Eswatini is set to introduce the SHORRT therapy early next year, without having done a clinical trial or implementation research due to lack of funding. “As Eswatini we introduced the SHORRT injectable base regimens in 2014 and we’ve observed that it improved the treatment outcomes but we still noted that about 60% pf patients were experiencing problems such as hearing loss. And we also noted the high mortality rate which was above 10%, which is why moving forward. We want to introduce the short oral regimens beginning next year February,” says Nonhlanhla Dlamini, Programmatic Management of Drug Resistant TB (PMDT) coordinator in Eswatini.

She adds: “The challenge we faced was mainly funding to implement the operation research, but moving forward, I don’t think we will have any problems because the drugs which we will be using are the ones we are already using in the long regimens like the 18-20 months’ programme. Currently we have already developed the protocol, and starting with the ethics committee and we are waiting for the approval.”

Reduction in mortality rate

Dlamini says that they will only start rolling out the therapy at a few health facilities, while hoping to have the treatment available throughout the country at the end of 2020. “We are starting with a pilot of about five facilities that are two of the richest in Eswatini, and after that we will roll out to the entire country, but we have not yet implemented a clinical trial or any other operational research. The regimens that we are planning to implement are bed aquiline and linezolid for a period of nine to twelve months.”

In Lesotho they have begun with the clinical trial for SHORRT-therapy but they are still faced with a challenge of patients who cross the border to seek better medical services in South Africa. MDR-TB programme manager at Partners in Health in Lesotho, Lawrence Oyewusi says that they have seen a reduction in mortality rate since they have put the SHORRT-Therapy on clinical trial in their health facilities.

“Lesotho has not really adopted the use of SHORRT regimens but we are doing it under clinical trial. But the clinical trial is completely different from operational research… When you do things under clinical trial there are so many things you need to look at, such as monitoring the patients very well. So far we have enrolled a lot of patients and I think they are doing so well because, if you look at the programme in Lesotho the mortality rate used to be very high at the range 30–33%, but ever since we started using the new drugs, the mortality rate has been reduced to about 17%. With the clinical trial we have seen a lesser mortality rate,” says Oyewusi.

He says the clinical trial will take about five years because it is also occurring in other countries. “The enrolments will be for about two and a half years and the follow up will be for two years as we do not want to give a SHORRT regimens without being sure if patients will relapse or not [so] we have to do follow ups, but after the trial it is something which everyone is looking forward to. The longer regimens which we used to use are very toxic as it has a lot of toxic drugs in there, but now things are changing as instead of treating patients for 18 months you can actually reduce it to nine months and save a lot of money.” 

Progress in South Africa too

According to Dr Norbert Ndjeka, director of National TB and Management Cluster in South Africa, “When the country started using bedaquiline, we observed that the death rate was coming down slowly. We also noticed that we didn’t have any option for patients who developed ototoxicity, so we felt that maybe [it] is better than not to give an injectable to individuals who were [reacting] on toxicity.” Before that, Ndjeka says, patients had to choose to either to remain deaf or die. “We don’t like those options.” 

He says this is why South Africa started using bedaquiline and there was an improvement in treatment success rate and hearing loss also decreased. He tells Health-e News that they carried on with the same logic in the shorter regimen. “In our shorter regimen we achieved a treatment success rate of 67%, it has never happened before in South Africa, everything used to be below 50%.” Ndjeka says if everyone could be on this regimen, the country will achieve 75% treatment success rate. 

Jennifer Furin of Harvard Medical School says 500 000 people become sick with RR-TB each year, while only 156 071 (31%) are diagnosed and put on treatment. Only 51% of those diagnosed with TB have their strains tested for rifampicin resistance, and only 59% of those individuals received testing for second-line medications.

“New and repurposed drugs such as bedaquiline and linezolid are saving lives with shorter regimens leading to potentially more tolerable treatment as injectable-free regimens reduces exposure to toxic medications,” says Furin.

– Health-e News

Image credit: iStock

Share Button

Health24.com | ‘Cannabis use disorder’ up in states that legalised recreational dagga

States that legalised recreational marijuana have seen an increase in problematic pot use among teens and adults aged 26 and older, a new study finds.

The researchers compared dagga use in Colorado, Washington, Alaska and Oregon – the first four states to legalise recreational marijuana – before and after legalisation. The investigators also compared trends in those states with states that did not legalise recreational marijuana.

Preventing unintended harms

“There are, indeed, important social benefits that legalizing marijuana can provide, particularly around issues of equity in criminal justice,” said lead author Magdalena Cerda. She’s director of the Center for Opioid Epidemiology and Policy at NYU Langone Health, in New York City.

However, “our findings suggest that as more states move toward legalising marijuana for recreational use, we also need to think about investing in substance use prevention and treatment to prevent unintended harms – particularly among adolescents,” Cerda added in an NYU news release.

The study authors examined marijuana use and frequent use (more than 20 days) in the past month, and problematic marijuana use (also called “cannabis use disorder”) over the past year. Signs of problematic use include increased tolerance, repeated attempts to control use or quit, spending a lot of time using, social problems due to use, and ignoring other activities in order to use.

The rate of problematic use among teens aged 12 to 17 rose from 2.18% to 2.72% after legalisation, and was 25% higher than in non-recreational states. But there was no change in rates of past-month or frequent use.

Among adults 26 or older, past-month marijuana use after legalisation was 26% higher than in non-recreational states. Past-month frequent use rose by 23% and past-year problematic use rose by 37%.

Benefits and potential harms

Among young adults aged 18 to 25, there was no increase in past-month, frequent or problematic marijuana use after legalisation, according to the study. The findings were published online in JAMA Psychiatry.

According to study senior author Dr Silvia Martins, “Cannabis use disorder in adolescence is associated with long-term adverse health, economic and social consequences.” She is an associate professor of epidemiology at Columbia University Mailman School of Public Health, in New York City.

“Given our findings on problematic use across age groups, legalisation efforts should coincide with prevention and treatment,” Martins said in the news release.

“The general public should be informed about both benefits and potential harms of marijuana products to make informed decisions,” Martins added.

Recreational marijuana use is legal in 11 states and Washington, D.C. Medical marijuana use is legal in 33 states, the study authors noted.

Image credit: iStock

Share Button

‘Sugar overload’ warning for festive hot drinks

Seasonal lattes and hot chocolates sold by coffee chains can contain up to 23 spoonfuls, a study finds.

Share Button

Antarctic ice sheets could be at greater risk of melting than previously thought

Antarctica is the largest reservoir of ice on Earth — but new research by the University of South Australia suggests it could be at greater risk of melting than previously thought.

Heat from the landmass beneath the Antarctic ice sheet is a major contributor to the way that glaciers melt and flow — and their impact on potential sea level rise. Hotter conditions allow meltwater to lubricate the base of the glacier, accelerating its movement and the rate of ice loss.

However, because of the environmental, logistical and financial challenges of accessing bedrock through ice up to several kilometres thick, drillcore samples have never been taken to directly measure the temperature conditions at the base of the ice sheet. Scientists therefore assume a fixed value for the amount of heat generated by the Earth’s crust in Antarctica — as if the bedrock was uniform when in fact it’s highly variable.

Research by UniSA is challenging these assumptions and suggests scientists may have underestimated the heat generated by the bedrock in East Antarctica.

UniSA PhD student Alicia Pollett, under the supervision of UniSA Associate Professor of Geology and Geochemistry Tom Raimondo, has used samples from a Geoscience Australia / SA Department of Energy & Mining drilling program in South Australia’s far west, in an area called The Coompana Province, to estimate heat flow in East Antarctica. Australia and East Antarctica were conjoined 160 million years ago.

“The findings show that there is significant variability in the heat generated by the bedrock in southern Australia that was previously joined to Antarctica,” Assoc Prof Raimondo says.

“Because East Antarctica and southern Australia were once part of the same landmass, almost like two pieces of the same jigsaw puzzle, we can extrapolate the data from the coastline of Australia to its matching coastline in Antarctica with a high level of confidence.

“Our research provides a more robust model for heat flow in East Antarctica.

“The results suggest scientists have underestimated the amount of heat generated from naturally occurring radiation in the rocks beneath East Antarctica — meaning that large areas are potentially more vulnerable to ice sheet movement and accelerated melting than we previously thought.”

The rocks beneath the ice sheets generate heat because they contain small amounts of the elements uranium, thorium and potassium, which undergo natural radioactive decay to release heat.

UniSA PhD student Alicia Pollett says the research findings will allow scientists to more accurately estimate the effect of geothermal heat flow from the Antarctic crust on the ice above.

“This is the first step towards a more representative heat flow map of the Antarctic crust, which will assist the scientific community to more accurately predict sea level rise caused by melting ice,” she says.

Although it hasn’t yet been possible to obtain core samples of bedrock in Antarctica, the glaciers themselves have served a useful purpose in exposing the rocks at their base. The glaciers pick up rocks as they move across the landscape and eventually deposit them as debris at their edges and ends.

Assoc Prof Raimondo says these samples, including some collected on the expedition led by Sir Douglas Mawson between 1911 and 1914, allow them to develop a “virtual drillcore” which can be used to help calculate heat flow maps.

“Our next ambition is to produce a web-based map containing a compilation of all published and legacy geological data from decades of research in Antarctica and to make it available to all researchers,” he says.

The research paper, Heat flow in southern Australia and connections with East Antarctica, is published in the journal of Geochemistry, Geophysics, Geosystems.

Key facts

  • Of the basic parameters that shape and control ice flow, the most poorly understood is geothermal heat flow
  • Antarctic-wide heat flow maps have been previously based on satellite magnetic or seismological data (geophysical models rather than direct sampling)
  • UniSA researchers have produced the first regional heat flow map of an area that was formerly conjoined to East Antarctica — the Coompana Province, which straddles the South Australian-Western Australian border. It is located between the western Gawler Craton to the east, the Musgrave Province to the north and the Madura Province (Western Australia) to the west. Because the Coompana Province was formerly part of the same landmass as Antarctica (the supercontinent Gondwana) it can be used to more accurately model heat flow maps for that part of Antarctica
  • The research by UniSA suggests traditional geophysical models underestimate the heat flow that contributes to subglacial melting.
  • The new measurements in the Coompana Province correspond to the Totten Glacier catchment, which has previously been shown to be thinning at an accelerated rate compared to other glacial regions of Antarctica.
  • 99 per cent of Antarctica is covered by ice, much of which is on average up to 2km thick. While there are drill holes in Antarctica, they are all relatively shallow — none have intersected the bedrock beneath.
  • East Antarctica, also called Greater Antarctica, constitutes about two-thirds of the Antarctic continent, lying on the Indian Ocean side of the continent, separated from West Antarctica by the Transantarctic Mountains.

Story Source:

Materials provided by University of South Australia. Note: Content may be edited for style and length.

Share Button

Antarctica’s thinning ice shelves causing more ice to move from land into sea

Researchers have produced the first physics-based quantifiable evidence that thinning ice shelves in Antarctica are causing more ice to flow from the land into the ocean.

Their findings have been published in Geophysical Research Letters.

Satellite measurements taken between 1994 and 2017 have detected significant changes in the thickness of the floating ice shelves that surround the Antarctic Ice Sheet. These shelves buttress against the land-based ice, holding them in place like a safety band.

While it has been suggested that the thinning ice shelves were responsible for a direct loss of ice from the land-based ice sheet into the ocean, there was no actual evidence linking data and physics that could demonstrate this, until now.

Researchers in the UK and US have now undertaken the first continent-wide assessment of the impact the thinning ice shelves are having on the flow of ice in Antarctica.

They were particularly interested in seeing how much ice flowed across the ‘grounding line’. This is the point where the land-based ice sheet meets the sea-based ice shelves.

They used a state-of-the-art ice-flow model developed at Northumbria University, UK, and newly available measurements of changes in the geometry of ice shelves to calculate the changes in grounded ice flow.

When the modelled results were compared with those obtained by satellites over the last 25 years, the researchers found what they described as ‘striking and robust’ similarities in the pattern of ice flowing from the ice sheet into the ocean.

The largest impact was found in West Antarctica, which already makes a significant contribution to sea level change. The largest changes are taking place around the Pine Island and Thwaites glaciers. On Pine Island Glacier, evidence of these changes could be seen almost 100 miles (150km) inland, upstream of the grounding line.

Hilmar Gudmundsson, Professor of Glaciology and Extreme Environments at Northumbria University led the study. He said there has been a long-standing question as to what was causing the changes we have observed in land-based ice over the last 25 years, and that while the thinning of the floating ice-shelves had been suggested as a reason, the idea had never been put to the test before now.

“I found it striking how well our modelled changes agree with the pattern of observed mass loss,” he said.

“There are other processes in play as well, but we can now state firmly that the observed changes in ice-shelves do cause significant changes over the grounded ice, speeding up its flow into the ocean.”

A critical element of the findings was the speed at which the ice flowed from the sheet into the ocean as a result of the thinning ice shelves.

“One of the most important lessons from this study is that the impact is felt without any delay,” said Professor Gudmundsson.

“Generally, we distinguish between an instantaneous response or a delayed, transient response. Our study shows the thinning of the ice shelves results in a significant instantaneous response to ice flow and ongoing mass loss. This means that we are not protected against the impact of the Antarctic Ice Sheet on global sea levels by a long response time.”

He added: “This study closes an important hole in our understanding. Lack of data and limitations in modelling previously made it challenging to quantify the importance of ocean-induced changes as a driver for ongoing mass loss, but we have now shown that the observed ice shelf changes do indeed impact on upstream flow significantly.”

The research was led by Northumbria University, Newcastle in the UK, with the NASA Jet Propulsion Laboratory and the Scripps Institution of Oceanography at the University of California San Diego.

Helen Amanda Fricker, Professor at Scripps Institution of Oceanography, said: “Ice shelves are the most vulnerable parts of Antarctica’s ice sheet system and we know that they are shrinking, but what we didn’t know before this work was how that was impacting the grounded ice behind them.”

Fernando Paolo, postdoctoral scholar at Jet Propulsion Laboratory/California Institute of Technology, added: “It is striking how far inland the changes in ice shelves can impact the ice sheet flow. Since we now know that shrinking ice shelves are directly responsible for increases in ice discharge to the ocean, it is important that we keep monitoring them to watch how they evolve.”

It is believed that the ice shelves may be thinning due to changes in ocean heat content, either by ocean warming or from changes in how the ocean circulates around and below the shelves, but further research is needed to establish the specific reasons.

It was partially funded through both the International Thwaites Glacier Collaboration’s PROPHET project and through the recently announced TiPACCs study, which are respectively funded by the Natural Environment Research Council/National Science Foundation and European Union’s Horizon 2020 research and innovation programme.

Share Button

Sweet potato uses a single odor to warn its neighbors of insect attack

Sweet potatoes (Ipomoea batatas) are becoming more and more popular: Whether in soup or as fries, they increasingly compete with “regular” potatoes which, surprisingly, are only distantly related. Although economically not as important as the potato world-wide, the sweet potato has a higher nutritional value and is richer in vitamins. Particularly in Asia, the crop is an important source of nutrients. As with potatoes, there are different cultivars of sweet potatoes available, all displaying their own characteristics. Even cultivars grown in the field under similar conditions may differ strikingly with respect to insect attack. In previous studies, a cultivar known as Tainong 57 had demonstrably higher resistance to field herbivores in comparison to the cultivar known as Tainong 66. When attacked, the plants’ leaves emit a distinct odor bouquet. Researchers at the Max Planck Institute for Chemical Ecology in Jena, Germany, and at the National Taiwan University wanted to find out whether the high insect resistance in one cultivar was related to this odor. They especially wanted to know whether sweet potatoes have mechanisms to activate defense responses via volatile signals, as described in other plant species.

First the scientists examined what happens in a plant after it has been attacked by herbivores. Plants of the resistant cultivar synthesize a plant hormone in the wounded leaves that is important for activating defense mechanisms. These plants also emit a bouquet of odors. As a result, a substance (sporamin) is formed in Tainong 57 leaves that are not directly affected by attack. Sporamin inhibits digestive enzymes in the attacking insects and causes the herbivores to completely lose their appetite. At the same time, sporamin is the dominant storage protein in the tuber and the reason why sweet potatoes must be cooked before being consumed. In the odor bouquet, only a single substance, DMNT, is responsible for this defense response: “DMNT is a terpene compound and smells almost a bit like herbal balm. One could imagine it as a fragrance used in a sauna,” says Anja Meents, first author of the study and doctoral researcher at the MPI for Chemical Ecology, describing the scent. DMNT triggers the formation of the defense protein not only in the affected plant but also in neighboring plants that have not yet been attacked by herbivores. These plants are able to perceive the smell quickly and efficiently in order to prepare themselves to meet the impending threat.

“To our surprise, only one single volatile is enough to induce a specific defense reaction in a sweet potato plant of the Tainong 57 cultivar. Moreover, the same substance is simultaneously used by the plant for communication with neighboring plants in order to transmit important information,” points out Axel Mithöfer, head of the Research Group Plant Defense Physiology. Interestingly, only plants of the resistant Tainong 57 cultivar released DMNT in high concentrations and were able to perceive the odor. Plants of the Tainong 66 cultivar, in contrast, released significantly less DMNT; even when the level of DMNT was increased, plants of this herbivore-susceptible sweet potato cultivar were unable to improve the effectiveness of their defense response.

“Our results are of great agricultural importance, because the consistent cultivation of resistant cultivars, such as Tainong 57, could help to considerably reduce the damage caused by herbivores in a natural way,” Meents explains, indicating the practical potential of the study. The development of cultivars that release higher amounts of DMNT and which can perceive DMNT more efficiently compared to the cultivars in the study could further minimize the use of pesticides.

In further studies, the team of researchers would like to examine more closely how Tainong 57 perceives DMNT and transfers the signal into a defense response.

Story Source:

Materials provided by Max Planck Institute for Chemical Ecology. Note: Content may be edited for style and length.

Share Button

Health24.com | Seven things every HIV patient should know about switching to new med DTG

Launch of government’s long-awaited new antiretroviral therapy (ART) guidelines, including the widespread roll-out of the medicine dolutegravir, is imminent.

While hailed by some as a wonder drug, like any other new drug dolutegravir comes with risks and benefits and patients deserve the right to be fully informed before deciding whether they would like to take this new medication. Dolutegravir will be offered to new, returning, and stable patients with suppressed viral load, with the latter making up by far the largest group.

Most of these patients currently take efavirenz and will be offered a single drug substitution to dolutegravir. The new guidelines will suggest that all patients should be counselled about the risks and benefits of making this switch. The following is a list of issues that should be discussed with any patient considering a switch from efavirenz to dolutegravir:

1. Safety in pregnancy

Efavirenz is known to be very safe in pregnancy. There is a roughly eight-fold increased risk of neural tube defects (NTDs) such as spina bifida in women who conceive while taking dolutegravir compared to efavirenz. It’s worth remembering that the absolute risks of NTDs on dolutegravir remains low at about three per 1000 births, but the birth defects are serious.

Can anything be done?

As well as avoiding unintended pregnancy with contraception, it may be possible to mitigate the risk of NTDs by taking folate (folic acid) around the time of conception. This is good advice for any woman wishing to fall pregnant but is so far an unproven strategy for reducing the risks of dolutegravir in pregnancy.

2. Weight gain

Unfortunately, there have been no large-scale randomised studies on the effects of switching from efavirenz to dolutegravir, which makes it difficult to know exactly what will happen. However, studies of new and returning patients, who all tend to put on weight as they return to health, show that patients on dolutegravir tend to put on more weight than those on efavirenz – around 2kg extra in the first two years. The difference is most pronounced in black women; weight may continue to rise beyond two years, and may be aggravated by certain contraceptive methods.

Whilst this cannot necessarily be extrapolated to patients who are currently stable on efavirenz, most experts believe that patients, and particularly black women, will tend to gain weight if they make the switch. It’s not known how much weight they will gain or whether the weight gain levels off over time.

Can anything be done?

Patients who have undesirable weight gain on dolutegravir could request to switch back to efavirenz in the hope that their weight will return to where it was before. 

3. Drug interactions

Both dolutegravir and efavirenz interact with other drugs (don’t mix well in the body). Drug interactions can lead to either toxic or sub-therapeutic levels of either ART or the interacting drug. Dolutegravir generally has less drug interactions than efavirenz but an important one is with rifampicin, the most important drug in standard TB treatment.

Dolutegravir must not be taken with anti-acid medications and can increase blood levels of metformin, a common drug for treating diabetes .Efavirenz has no significant interaction with rifampicin but cannot be taken with some epilepsy medications and can make some hormonal contraceptives less effective. There is a list of other medications that you might require for a shorter period that cannot be taken with efavirenz. 

Can anything be done?

Dolutegravir can be taken twice a day when also taking rifampicin, anti-acids can be safely taken at different times of day, and the dose of metformin can be reduced. Patients on efavirenz may need to use alternative methods of contraception and anti-epileptics and sometimes temporarily switch to another ARV if the interacting drug is only required for a short time.

4. Barrier to resistance

Dolutegravir has a much higher ‘barrier to resistance’ than efavirenz which means that it’s harder for the HIV virus to become resistant to dolutegravir. In practical terms, this means that if patients have difficulty taking their ARVs every day, or stop taking them completely, there is more chance of dolutegravir working in the future than efavirenz. This is of limited relevance to virally suppressed patients who rarely or never miss their medication but might be important for patients who struggle with daily pills. 

Can anything be done?

Patients who do develop resistance to efavirenz would be able to switch to dolutegravir at that point.

5. Short term side-effects

Patients who are currently taking efavirenz may remember some unpleasant side-effects in the first few weeks that they took it, particularly dizziness and vivid dreams. While this will now have passed, there is a risk of new short-term side-effects with dolutegravir. The commonest complaint with dolutegravir is insomnia.

Can anything be done?

Short-term side-effects usually ware off over the first few weeks. Patients suffering insomnia with dolutegravir can take their medication when they wake up.

6. Long term side-effects

The long-term side-effects of efavirenz are quite well known as it has now been used extensively in South Africa since 2005. Liver injury can occur in up to 8% of patients and usually begins in the first eight weeks of starting therapy, so patients who have been taking efavirenz for several years without liver injury are less likely to be affected.

There is some evidence that long-term exposure to efavirenz has a negative effect on brain function in some patients, and this can be worsened when taking isoniazid as TB preventive therapy.The long-term side-effects of dolutegravir are largely unknown so far as it has not been taken by large numbers of patients for long enough. There therefore remains the possibility of as yet unknown but serious side-effects.

So far, there has been a preliminary study showing that patients taking dolutegravir have smaller brains than those who take other ARVs, but this is yet to be confirmed.

Can anything be done?

The current fixed dose combination with efavirenz contains 600mg of the drug. It is known that 400mg of efavirenz is just as effective so it may be possible to decrease the dose and therefore the side effects with no ill effects. 

7. Service delivery

The new guidelines will state that patients can only be switch to dolutegravir if they have a suppressed viral load result within the past six months. This creates a problem for the approximately 1.9 million clinically stable patients who are currently enrolled in differentiated service delivery (DSD) models such as spaced fast lane, facility-based or community-based adherence clubs or external pick-up points.

These patients only have a viral load taken once a year. So, in order to switch within the current guidelines, they would need to make at least one extra visit to see a clinician at their clinic. This may be a significant barrier to many patients who find it difficult to take time off work or childcare to attend clinics, as well as an unwanted burden on the healthcare system.

Can anything be done?

There is little that patients can do about this but a change in the guidelines to allow patients in DSD models with long-term suppression to switch to dolutegravir with a viral load result that is one year old would solve the problem.

Conclusion

In conclusion, there are multiple competing risks and benefits of virally suppressed patients switching from efavirenz to dolutegravir, making counselling a complex issue. Patients are likely to perceive the risks differently based on factors such as childbearing potential or desire, attitude to weight gain, fear of long-term side-effects, and the need for other medications.

All patients deserve to be fully informed of all these issues and have an opportunity to discuss their individual case. Given the large number of clinically stable patients in South Africa, it will be a mammoth task for a pressurised public health system. However, failure to properly discuss these issues will be a failure to provide a level of service that our patients deserve.

Dr Tom Boyles is an infectious diseases consultant at Helen Joseph Hospital, Johannesburg.

This article first appeared in Spotlight.

Image credit: iStock

Share Button

Child life expectancy projections cut by years

Children born this year expected to live shorter lives than previously thought, say official stats.

Share Button

Morning-after pill ‘should be sold off the shelf’

A report says accessing contraceptives and abortion pills in the UK should be easier for girls and women.

Share Button